Obalon Therapeutics, Inc. (OBLN) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Obalon Therapeutics, Inc. (OBLN) Healthcare & Pipeline Overview

Obalon Therapeutics, Inc. is a medical device company focused on innovative weight reduction solutions for obese patients. Its Obalon Balloon System, featuring an ingestible, inflatable balloon, aims to provide a minimally invasive option in the competitive obesity treatment market, operating from its Carlsbad, California base.

What Is the Investment Thesis for OBLN?

Obalon Therapeutics, Inc. operates in the growing market for minimally invasive weight loss solutions, positioning its Obalon Balloon System as a key offering for obese patients. The company's unique ingestible balloon technology provides a differentiated approach compared to traditional pharmaceutical or surgical interventions. With a reported gross margin of 58.5%, Obalon demonstrates efficiency in its core operations, indicating a strong unit economic potential for its medical device. The company's significant profit margin of 1539.0% suggests effective cost management or specific financial events, which warrants further investigation into its sustainability. However, the company's small market capitalization of $5.47M and a beta of -1.24 indicate a highly volatile and potentially niche market position. Key value drivers include the potential for increased market penetration of its minimally invasive system, especially as demand for non-surgical obesity treatments rises. Growth catalysts could stem from expanding its treatment center network beyond the three California locations reported in early 2020, or through strategic partnerships that broaden its geographic reach and patient access. Investors should monitor the company's ability to scale its operations, manage competitive pressures from established players, and maintain its profitability amidst market dynamics.

Based on FMP financials and quantitative analysis

OBLN Key Highlights

Market capitalization stands at $0.01 billion, indicating a micro-cap valuation within the medical device sector.

• Reported profit margin of 1539.0% reflects exceptional profitability, potentially influenced by specific financial events or operational efficiencies.
• Gross margin of 58.5% demonstrates strong profitability on its core product sales, exceeding many industry benchmarks.
• The company operates with a lean structure, employing 2 individuals, suggesting a highly focused or outsourced operational model.
• Beta of -1.24 indicates an inverse relationship with market movements, suggesting lower systematic risk or unique market dynamics.

Who Are OBLN's Competitors?

OBLN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OBLN's Key Strengths?

Proprietary Obalon Balloon System offers a unique, ingestible, minimally invasive weight loss solution.

• High gross margin of 58.5% indicates strong profitability on product sales.
• Integrated system with navigation and inflation tools provides a comprehensive treatment platform.
• Established three company-owned treatment centers (as of Feb 2020) for direct patient engagement.

What Are OBLN's Weaknesses?

Small market capitalization ($0.01B) and only 2 employees suggest limited scale and resources.

• Geographic reach limited to three California treatment centers (as of Feb 2020).
• Product is specific to obesity, limiting diversification within the broader healthcare market.
• Negative beta (-1.24) indicates unusual market sensitivity or specific company-level factors.

What Could Drive OBLN Stock Higher?

OBLN catalyst: Increasing global prevalence of obesity driving demand for effective weight loss solutions, including minimally invasive devices.

• Continued market acceptance and adoption of non-surgical, ingestible balloon systems as a viable alternative to traditional bariatric interventions.
• Potential for expansion of the company's treatment center network or strategic partnerships to broaden geographic reach and patient access beyond California.
• Further clinical data or post-market studies demonstrating long-term efficacy and safety of the Obalon Balloon System, potentially expanding its addressable market.

What Are the Key Risks for OBLN?

Financial-distress signal — its Altman Z-Score of -14.83 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition from established pharmaceutical companies offering weight-loss drugs and surgical weight loss interventions.
• Challenges in gaining significant market share and widespread adoption against entrenched treatment methods and competitor devices.
• High operating expenses relative to revenue, requiring diligent cost management to sustain profitability and growth.
• Regulatory hurdles and the need for continuous compliance and potential new approvals for product enhancements or market expansions.
• Reimbursement challenges and varying insurance coverage policies for novel weight loss devices, impacting patient access and affordability.

What Are the Growth Opportunities for OBLN?

• Expansion of Minimally Invasive Treatment Adoption: The global prevalence of obesity continues to rise, driving demand for effective and less invasive treatment options. Obalon's ingestible balloon system directly addresses this need by offering a non-surgical alternative to bariatric surgery or long-term pharmaceutical regimens. The market for minimally invasive obesity devices is projected to grow significantly, with estimates suggesting a multi-billion dollar valuation in the coming years. Obalon has the opportunity to capitalize on increasing patient and physician preference for procedures that offer reduced recovery times and lower risks compared to traditional surgery, potentially expanding its market share over the next 3-5 years.
• Geographic and Distribution Network Expansion: As of February 2020, Obalon Therapeutics operated three company-owned treatment centers exclusively in California. A significant growth opportunity lies in expanding its operational footprint beyond this limited geographic scope. This could involve establishing new company-owned centers in other high-demand U.S. markets, or more efficiently, forming strategic partnerships with existing bariatric clinics, gastroenterology practices, or hospital networks across the nation and potentially internationally. Such expansion would broaden patient access to the Obalon Balloon System, tapping into larger patient populations and increasing revenue streams over a 2-4 year timeline.
• Product Line Extension and Enhancement: While the Obalon Balloon System is the flagship product, ongoing research and development could lead to enhancements or new iterations of the device. This might include developing balloons with different inflation volumes, materials, or deployment mechanisms to cater to a wider range of patient anatomies or weight loss goals. Furthermore, integrating the system with digital health platforms for patient monitoring, dietary guidance, and behavioral support could create a more comprehensive and appealing solution. These innovations could differentiate Obalon from competitors and open new market segments within the obesity management continuum, with potential developments emerging within 3-5 years.
• Strategic Partnerships and Collaborations: Collaborating with major healthcare providers, insurance companies, or pharmaceutical firms represents a substantial growth avenue. Partnerships with large health systems could facilitate broader adoption and reimbursement for the Obalon Balloon System, overcoming potential barriers to access. Similarly, co-promotion agreements with pharmaceutical companies that offer complementary weight-loss medications could create integrated treatment pathways. These strategic alliances could significantly accelerate market penetration and brand recognition, leveraging established networks and resources to reach a larger patient base, with potential impacts unfolding over the next 2-5 years.
• Targeting Broader Patient Demographics: The Obalon Balloon System is designed for obese patients, but specific indications and patient profiles can be expanded. Research into the efficacy and safety for patients with different BMI ranges, co-morbidities, or those who have failed other weight loss interventions could open up new addressable markets. Expanding the clinical evidence base to support use in a broader demographic, potentially through post-market studies or new clinical trials, could lead to expanded regulatory approvals or recommendations. This strategic focus would allow Obalon to serve a larger segment of the obese population, enhancing its market relevance and revenue potential over a 3-6 year horizon.

What Threats Does OBLN Face?

• Intense competition from established pharmaceutical weight loss drugs and bariatric surgery.
• Regulatory hurdles and approval processes for medical devices.
• Potential for new, more effective or cheaper competing technologies to emerge.
• Reimbursement challenges and insurance coverage limitations for novel weight loss devices.

What Are OBLN's Competitive Advantages?

• Proprietary ingestible balloon technology, offering a unique, minimally invasive delivery method.
• Integrated system including navigation and inflation tools, creating a comprehensive solution.
• Established company-owned treatment centers (as of Feb 2020) providing direct patient access and control over the treatment experience.

What Does OBLN Do?

Obalon Therapeutics, Inc., established in 2008 and headquartered in Carlsbad, California, operates as a fully integrated medical device enterprise dedicated to developing and commercializing innovative solutions for individuals grappling with obesity. The company's core offering is the Obalon Balloon System, a proprietary technology specifically engineered to facilitate weight reduction in obese patients. This comprehensive system represents a minimally invasive approach, distinguishing itself from traditional surgical interventions and offering an alternative to pharmaceutical or more invasive surgical options. The system's design incorporates several key components: an ingestible capsule that houses an inflatable balloon, which is connected to a microcatheter for precise deployment. This innovative delivery method aims to simplify the procedure for both patients and clinicians. Complementing this is the Obalon Navigation System console, a specialized hardware and software platform crucial for accurately monitoring and displaying the balloon's location during its placement within the patient, ensuring safety and efficacy. Further enhancing the system's functionality is the Obalon Touch Inflation Dispenser, a semi-automated, portable instrument designed for the controlled inflation of the balloon once it has been correctly positioned. A single-use canister containing a specific gas mixture completes the system, ensuring proper and consistent inflation. By February 27, 2020, Obalon Therapeutics had established and managed three company-owned treatment centers, all strategically located within California, serving as direct points of care and demonstrating a vertically integrated approach to product delivery and patient management. The company's evolution has centered on addressing the significant public health challenge of obesity through technological innovation in medical devices, aiming to provide accessible and effective weight loss tools.

What Products and Services Does OBLN Offer?

• Develops and commercializes medical devices specifically for obesity treatment.
• Offers the Obalon Balloon System, an ingestible, inflatable balloon designed for weight reduction.
• Manufactures an ingestible capsule containing a balloon connected to a microcatheter.
• Provides the Obalon Navigation System console for monitoring balloon placement.
• Supplies the Obalon Touch Inflation Dispenser for semi-automated balloon inflation.
• Manages three company-owned treatment centers in California for product delivery (as of Feb 2020).
• Focuses on minimally invasive solutions as an alternative to surgical or pharmaceutical interventions.

How Does OBLN Make Money?

• Sells the Obalon Balloon System, including its components (capsule, navigation system, inflation dispenser, gas canister) to healthcare providers or directly to patients through its treatment centers.
• Generates revenue from the procedures performed using its proprietary medical device.
• Potentially earns revenue from ongoing support or maintenance related to the Obalon Navigation System console and inflation dispenser.

What Industry Does OBLN Operate In?

Obalon Therapeutics, Inc. is positioned within the dynamic and expanding medical devices industry, specifically targeting the obesity treatment market. This sector is characterized by a growing demand for effective, less invasive solutions due to the global rise in obesity rates. The competitive landscape includes established pharmaceutical companies offering weight-loss drugs, traditional bariatric surgery providers, and other medical device firms developing alternative minimally invasive procedures. Obalon's Obalon Balloon System, an ingestible, gas-filled balloon, aims to carve out a niche by offering a non-surgical, reversible option for weight reduction. The broader market trend favors solutions that reduce recovery times and associated risks, aligning with Obalon's product profile. However, gaining significant market share requires overcoming the inertia of established treatment protocols and demonstrating superior long-term efficacy and safety compared to a diverse array of competitors.

Who Are OBLN's Key Customers?

• Obese patients seeking non-surgical weight reduction solutions.
• Healthcare providers, including bariatric clinics, gastroenterologists, and weight management centers.
• Individuals who may not qualify for or prefer to avoid traditional bariatric surgery.

Obalon Therapeutics, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 52.7% below estimates on average.

Quarterly Financial Performance: Obalon Therapeutics, Inc.

Revenue for Obalon Therapeutics, Inc. came in at $27K during Q2 2026, a 14.7% contraction versus the preceding quarter. The company recorded a net loss of $686K, with diluted EPS of $-0.10. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely.

OBLN Valuation & Market Position

With a $5.47M market cap, Obalon Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, OBLN's quantitative score of 48/100 is below the peer average of 65/100.

Obalon Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -14.83 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Obalon Therapeutics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Kelly Huang. OBLN has traded publicly since 2016.

OBLN Financials

OBLN Latest News

No recent news available for OBLN.

OBLN Analyst Consensus

OBLN MoonshotScore

What Investors Ask About Obalon Therapeutics, Inc. (OBLN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources